In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells
| Autor: | S Kole, Z Ciftci, Istvan Vermes, C Haanen, H.R. Franke |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Cancer Research
medicine.medical_specialty Programmed cell death Time Factors Antineoplastic Agents Hormonal medicine.drug_class Estrogen receptor Apoptosis Breast Neoplasms Biology Cyclin D1 Breast cancer Internal medicine Tumor Cells Cultured medicine Humans skin and connective tissue diseases Antineoplastic Agents Alkylating Cyclophosphamide Cell Nucleus Cell Death Estradiol Progesterone Congeners Reverse Transcriptase Polymerase Chain Reaction Mucins medicine.disease Tamoxifen Endocrinology Receptors Estrogen Oncology Estrogen Cancer cell Dydrogesterone Cell Division medicine.drug |
| Zdroj: | Cancer Letters. 190:113-118 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/s0304-3835(02)00546-3 |
| Popis: | The effects of 17 beta-estradiol, dihydrodydrogesterone, tamoxifen and cyclophosphamide upon parameters of cell maturation (Mucine1 expression), cell proliferation (Cyclin D1 expression) and apoptosis (loss of nuclear DNA) were studied in estrogen receptor positive (ER+) and negative (ER-) human breast cancer cells. Tamoxifen was the most potent inducer of apoptosis in ER+ and ER- breast cancer cells. 17 beta-estradiol in a concentration of 10(-6) M induced proliferation in ER+ cells after 144 h. incubation, while equimolar co-incubation with dihydrodydrogesterone prevented this effect and even induced a significant increase of cell death. It is speculated that the continuous use of combined 17 beta-estradiol plus dihydrodydrogesterone might be given as hormone replacement therapy without increased risk of breast cancer and even may reduce the relapse rate in breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect